Progress towards an amebiasis vaccine.
Amebiasis (infection by Entamoeba histolytica) remains a major health problem in much of the developing world. Morbidity and mortality from amebic dysentery and amebic liver abscess have persisted despite the availability of effective anti-amebic therapy, suggesting a need for alternative measures of disease control. Through the application of recombinant DNA technology, several E. histolytica antigens have now been expressed in prokaryotic systems and tested in animal models as vaccines to prevent invasive amebiasis. In this review, Sam Stanley Jr discusses why a vaccine for amebiasis may be feasible, and describes the recent development of several promising recombinant E. histolytica antigen-based parenteral and oral vaccine candidates.
Stanley
S L
SL
Department of Medicine and Molecular Microbiology, Washington University School of Medicine, Campus Box 8051, 660 South Euclid Avenue, St Louis, MO 63110, USA. sstanlet@visar.wustl.edu